“Tumour Necrosis Factor-alpha/an- tagonists and inhibitors”[MeSH] OR “golimumab” OR “tocilizumab” OR “rituximab” OR “Interferon Alpha- 2a” OR “Interferon Alpha-2b” OR “Interferon Alpha-2c”) AND (“Vascu- litis, Central Nervous System”[Mesh] OR “Giant Cell Arteritis”[Mesh] OR “Takayasu Arteritis”[Mesh] OR “Beh-

1Rheumatology Unit, Department of Internal Medicine, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy; 2Rheumatology Department of Lucania, Ospedale San Carlo di Potenza e Ospedale Madonna delle Grazie di Matera, Italy, on behalf of the Italian Society for Rheumatology. Nicolò Pipitone, MD, PhD Ignazio Olivieri, MD Carlo Salvarani, MD Please address correspondence to: Carlo Salvarani, MD, Dipertimento di Reumatologia, Arcispedale S. Maria Nuova, Viale Risorgimento 80, 42100 Reggio Emilia, Italy. E-mail: [email protected] Received on October 31, 2011; accepted in revised form on March 26, 2012. Clin Exp Rheumatol 2012; 30 (Suppl. 70): S139-S161. © Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2012.